Programming Cytokine Sensing: A Blueprint for Durable CAR-T

Online Inquiry

webinar recording 10 AM EST | December 11, 2025

Interferon-gamma (IFNγ) is a double-edged cytokine for adoptive cell therapy in solid tumors. While IFNγ is required for CAR-T cell efficacy against these cancers, its direct uptake by CAR-T cells with a CD28 costimulatory domain can restrict their expansion, persistence, and overall effectiveness. To address this challenge, new strategies are being developed to re-engineer CAR-T cells, allowing them to overcome their limitations and produce more durable antitumor responses.

We are honored to invite Dr. Bailey to introduce a novel approach that leverages cytokine-pathway editing to enhance CAR-T cell performance.

Join us to explore how deleting the IFNγ receptor (IFNγR) in CAR-T cells can uncouple their efficacy from attrition, leading to improved and lasting antitumor results in various solid tumor models. This strategy also highlights that engineering choices must consider the specific costimulatory domain (CD28 vs. 4-1BB) and that subset-aware strategies are crucial for optimizing persistence and function. Applying these principles will help create more durable, solid-tumor–ready CAR-T therapies for clinical use.

During this webinar, we will discuss the following key points:

How cytokine-pathway editing (e.g., IFNγ sensing) can be leveraged to uncouple efficacy from attrition.
Why engineering choices must be contextualized by costimulatory domain, as CD28 and 4-1BB parse cytokine cues differently.
How subset-aware strategies are essential to optimize persistence and function for CAR-T cells.

Speaker

Stefanie Bailey
Assistant Professor at University of Virginia

Dr. Bailey is an Assistant Professor at the University of Virginia, where her lab engineers next-generation CAR-T cells for solid tumors across pediatric and adult cancers. She earned her PhD in Microbiology & Immunology from the Medical University of South Carolina, identifying a human CD4+ T cell population with potent antitumor activity. She later completed postdoctoral training at Massachusetts General Hospital and Harvard Medical School, where she developed strategies to modulate interferon-gamma (IFNγ) signaling to improve CAR-T performance. Dr. Bailey’s team integrates precise gene editing with non-invasive technologies to enhance persistence, safety, and efficacy, with the goal of advancing CAR-T therapies towards clinical translation.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

Novel Solution. (Creative Biolabs Authorized)

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

New Technology. (Creative Biolabs Authorized)

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION